ImmunoMind

About:

Multi-Omics Driven Development of Effective Cell Therapies

Twitter/X: immunomind

Top Investors: SkyDeck Berkeley

Description:

ImmunoMind improves the design of T-cell therapies by precisely identifying T-cell subpopulations and their immune profile. ImmunoMind’s Augmented Intelligence platform guides translational and clinical research to improve the product’s quality, safety and efficacy with single-cell precision. The platform is based on proprietary single-cell multi-omics technologies to automatically evaluate cell differentiation, estimate exhaustion rate of subpopulations and identify off-tumor targets. UC Berkeley SkyDeck’20 Alumnus.

Total Funding Amount:

$755000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Berkeley, California, United States

Founded Date:

2020-01-01

Contact Email:

contact(AT)immunomind.io

Founders:

Sergey Fedyushchenko, Vadim Nazarov, Vasily Tsvetkov

Number of Employees:

11-50

Last Funding Date:

2022-01-01

IPO Status:

Private

Industries: